Caladrius Biosciences

Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

BASKING RIDGE, N.J., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020.

Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2020 Results - Earnings Call Transcript

BASKING RIDGE, N.J., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that it will report financial results for the three and six months ended June 30, 2020 after the close of the U.S. financial markets on Thursday, August 13, 2020.

Caladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020

BASKING RIDGE, N.J., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that Joseph Talamo, Chief Financial Officer (“CFO”), has tendered his resignation in order to explore opportunities outside of Caladrius. To ensure a smooth transition, Mr. Talamo plans to continue to serve as CFO until August 21, 2020. Caladrius has initiated a search to identify qualified candidates to fill the permanent CFO position and will provide an update in due course.

Caladrius Biosciences Announces the Resignation of Joseph Talamo, Chief Financial Officer

BASKING RIDGE, N.J., July  28, 2020  (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced the appointment of Michael H. Davidson, MD to its Board of Directors. Dr. Davidson, an industry leader and expert in preventative cardiology and lipidology, is the Founder and Chief Scientific Officer of Corvidia Therapeutics, which recently announced its sale to Novo-Nordisk for $2.1 billion. Dr. Davidson also serves as Clinical Professor and Director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine.

Caladrius Biosciences Appoints Dr. Michael H.

Investors need to pay close attention to Caladrius Biosciences (CLBS) stock based on the movements in the options market lately.

Implied Volatility Surging for Caladrius Biosciences (CLBS) Stock Options

BASKING RIDGE, N.J., May  28, 2020  (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has closed on its previously announced sale of an aggregate of 2,084,850 shares of its common stock to several institutional and accredited investors, at a purchase price of $2.0625 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Under the purchase agreement, Caladrius has also issued to the investors unregistered warrants to purchase up to an aggregate of 1,042,425 shares of common stock.

Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Single administration of CLBS16 durably improves heart function and symptoms in patients with coronary microvascular dysfunction Single administration of CLBS16 durably improves heart function and symptoms in patients with coronary microvascular dysfunction

Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2020 Results - Earnings Call Transcript

BASKING RIDGE, N.J., April  27, 2020  (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has closed on its previously announced sale of an aggregate of 2,162,166 shares of its common stock to several institutional and accredited investors, at a purchase price of $2.3125 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Under the purchase agreement, Caladrius has also issued to the investors unregistered warrants to purchase up to an aggregate of 1,081,083 shares of common stock.

Caladrius Biosciences Closes $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

BASKING RIDGE, N.J., April  23, 2020  (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 2,162,166 shares of its common stock, at a purchase price of $2.3125 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Caladrius has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,081,083 shares of common stock. The closing of the offering is expected to occur on or about April 27, 2020, subject to the satisfaction of customary closing conditions.

Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure

Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage

BASKING RIDGE, N.J., April  22, 2020  (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that it has finalized an agreement to sell $10.9 million in New Jersey net operating losses (“NJ NOLs”) to a qualifying and approved buyer pursuant to the New Jersey Economic Development Authority (“NJEDA”)’s Technology Business Tax Certificate Transfer Program (the “Program”).  The Program enables qualifying New Jersey-based biotechnology or technology companies to sell a percentage of their NJ NOLs and research and development tax credits to unrelated qualifying corporations.

Caladrius Biosciences to Receive $10.9 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript

Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events

Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2019 Results - Earnings Call Transcript

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2019 Results - Earnings Call Transcript

Franco-Nevada C

Gentex

Top Ranked Momentum Stocks to Buy for July 25th

Caladrius Biosciences, Inc.'s (CLBS) CEO David Mazzo on Q1 2019 Earnings Conference Call Transcript

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2018 Earnings Conference Call Transcript

News for Caladrius Biosciences Stock (CLBS)